Mondosano Patient Portal

Patients are not aware of new therapeutic options. Patients do not know about benefits of clinical research participation. Patients have preconceptions around clinical trials. 

Today, three in four deaths are caused by chronic conditions and roughly one in three adults suffer from several chronic conditions who are not aware of new therapeutic options, do not know about benefits of  clinical research participation and have caregivers who feel helpless and are also searching for support. At the same time there are more than 35,000 clinical trials active and in need of enrolled patients globally. Unfortunately, 85% of all trials globally are delayed due to slow patient recruitment. And while 63% of informed patients are open to clinical trial participation 68% don‘t think they can find a study on their own or through their physician. And for patients with rare diseases there are often only a few sources of information available and much less activity in biopharmaceutical R&D towards new solutions. Hence the bar needs to be lowered to run studies, understand their disease and develop treatment options at all.

Selecting the right sites and patients for a study can significantly decrease trial cost for sponsors and speed up time on market (under patent protection). New trial technology, more transparency and collaboration between all stakeholders like sites, physicians, patients and industry is needed in the healthcare ecosystem.

Mondosano empowers patients to take more charge of their health with simple and personalized access to information and participation in clinical research, patient-centric development activities and specific health information guides from trusted sources. Social groups offer peer exchange with other patients which help in better outcomes. 

Currently the platform counts about 100k patients in all main chronic disease indications and a rising number of rare diseases as well. In the aftermath of the pandemic, focus is on quickly scaling the number of registered users and optimizing the disease recruiting and engagement models.

Mondosano supports B2B-customers with fast access to patients and sites for clinical trials, conducts qualitative and quantitative surveys & generates patient insights, and creates awareness campaigns through various online channels. 

Enabled by the current data and technology, patient populations can be filtered specifically for deeper insights based on rich profiles. Targeted outreach via e-mail and telephone for fast and objective information about opportunities, recruitment and engagement of patients. Contact to active research sites and patients allows for trial feasibility studies and patient-centric design prior to finalization of the study protocol. 

Mondosano’s platform and services follow HIPAA guidelines for all privacy and regulatory purposes. The platform and services are built on web technologies. The insights and analysis modules are built using data science technologies and clinical AI models. 

Mondosano’s assets for fast patient access and insights are as follow: 

• Patient Database - A curated database of millions of patients deidentified data for analysis and insights on cure recommendations, clinical trials recommendations, clinicians recommendation for rare and chronic diseases.

• Clinical Research Platform - A research platform for scientific collaboration among study sites and physicians, and inform stakeholders (pharmaceutical companies, patient advocacy groups) 

• Proprietary Recruitment Technology - Patient Recruitment and simulation platform for faster and equitable recruitment

Mondosano’s platform serves all patients and caregivers in need, from noncommunicable to rare diseases and helps them to connect with new therapy solutions, digital health and traditional clinical trials, patient advocacy groups, and clinicians. 

With Mondosano’s unique proposition of patient communities for insights and engagements, we are able to provide services to thousands of patients who are seeking clinical information and care. Our platform treats all patients equally thereby building a portfolio of equitable care systems for all underserved communities included as well. 

In our patient insights, we come across patients who are financially disabled, patients from indigenous communities. Our platform gives equal opportunity of care and services to all patients. 

We designed our clinical trial acceptance and validation system in a way that identifies patients as clusters of:

• rare diseases

• chronic diseases

• stage of the diseases 

• willingness to participate in clinical trials or patient engagement activities

The platform then allocates these patients to subsequent patient advocacy groups and pharmaceutical companies seeking clinical trial participation. 

We at Mondosano are a team of scientists, engineers, pharmacists, nurses and health economists with extensive experience in patient advocacy, clinical trials, and disease identification techniques. We are also equipped with marketing experts who have extensive prior experiences in online marketing, patient engagement and recommendation assistance. 

Our team represents the thousands of patients who have been onboarded on our platform from different communities. Our interaction with each patient while onboarding helps both parties (Mondosano and the patient) to understand the needs in terms of clinical guidance assistance or clinical trial assistance for any rare or chronic diseases. 

As we engage further, our platform curates and recommends the most feasible trials to the patients keeping certain factors in consideration such as geographical proximity, timings of trials, engagement propositions of the trials. 

In case of rare disease, our focus scopes to empower patients with quality and verified information about the disease and the progression possibilities. Our platform and team of medical practitioners recommend clinicians and verified clinical approaches to fight the stigma associated with certain rare diseases as per the conditions defined by the patient. Our community driven patient platform enables us to promote community and connection among rare disease patients and their advocates.

A pseudo clinical patient journey case study approach has been mentioned as below. 

A patient suffering and identified with disease ‘Idiopathic pulmonary fibrosis‘ based out of Berlin and looking for care protocols and secondary opinions for treatment. 

Some of the fields of information that get collected for analysis and interpretation are mentioned below.

• Rare Disease Identification Name

• Rare Diseases Identification ICD Code

• Patient Inputs

  • On Clinical Care

  • Need Clinical Assistance with

  • Age

  • Gender

  • On Oral Medication

  • On Clinical Treatment

  • Diseases symptoms

• Prior Clinician Consultation Inputs

  • Diseases Progression Stage

  • Disease age in patient

  • Disease symptoms validation

The above mentioned data points and other data points are taken in consideration for assigning the clinical care recommendations for the patient. Once the clinical data is also validated, the patient can be recruited for clinical trials or drug trials. 

Our team guides the patient throughout their journey of community engagements and provides verified information as per their disease conditions, to fight the stigma. 

We are looking for more potential avenues of exploring opportunities outside of Germany/German speaking Europe. We want to replicate the model of rare diseases care and verified care information. 

With MIT SOLVE, our approach towards the global market will be more impactful. We are driven with a vision to provide an equitable healthcare service to patients suffering from rare diseases. The award would help us focus on global avenues.

Mondosano generates surveys for patient recruitments, patients care analysis, rare disease queries using standardized  healthcare regulatory framework and diseases clustered under ICD-10/11 codes. These surveys help Mondosano platform to understand the patient needs and allocate the necessary care / services to the patients through a defined channel. 

To accelerate the rate of patient recruitment and increase adoption of care, Mondosano is also building another platform - Mondosano Clinical Trials Patients Discovery Platform. This platform would be an AI based privacy preserving equitable screening system to assist Clinical trials in patients recruitment and discovery phase to match clinical trials groups with patients and provide recommendations for selecting the most feasible clinical trial study group.

Mondosano will focus on two goals: Good Health and Well-Being (3) and Reduced Inequalities (10 ). We plan to significantly increase the dissemination of new therapy options, additional health support factors and existing programs like on- and offline programs to help with better diets, exercise, mental health. While a rising number of such programs are being covered by health insurance only a fraction of patients know about the opportunity and impact. Especially in terms of digital health apps, the uptake of such programs has been rather slow. Health innovators and entrepreneurs are often aware of such developments and follow via tech newsletters and events. The large share of the patient population is unaware of such offerings, prefers different channels and language. We will address this gap by constantly introducing a variety of offerings in patient / lay language via multiple channels and especially use active patients, who also serve as moderators in our social groups, to share their experiences and learnings as well.

Mondosano is using OKRs and the SMART framework to measure the progress and goals that are aligned with UN sustainable development goals (Goal 3 - Good Health and Well-Being, and Goal 10 - Reduced Inequalities ).

With the given framework, Mondosano puts its objective for process and purpose driven outcomes. 

Each process measure has an outcome - long-term and short-term. Few of the outcomes are discussed in the section of theory of change.

Mondosano is working towards two UN sustainable goals - Good Health and Well-Being (3), Reduced Inequalities (10). Our impact goals are driven by these mentioned sustainable goals. 

We believe that with our focused approach towards equitable clinical trials and patient diseases journeys in both rare, and chronic conditions. 

Activities

Patient Recruitment maintaining equitable healthcare protocols 

Rare Diseases Information Dashboard and empowerment with knowledge to fight the stigma

Rare Diseases treatment and clinical trials for underserved and all communities

Outputs

Actively recruiting ~1 M patients suffering from chronic diseases and ~10K rare diseases 

Patients can read and understand the clinically validated and verified protocols to be followed, as per disease conditions.  

Patients are able to communicate within communities to ensure their treatment plan and also network with peer patients and clinicians to ascertain their clinical trial participation. 

Short Term Outcomes

The Disease spread analysis can be understood based on the data collected. The Immediate outcome will be to identify the hospitalization burden and rate of increase of the disease with respect to conditions. 

Patients with rare diseases will be equipped with knowledge of supporting themselves in case of severe conditions, which do not yet call for hospitalization. This would help them to monitor and report their progress in conditions. 

The immediate outcome would be to determine the aspects of disease detection and how the patient can quickly be recommended to a clinical trial study group/ second opinion. 

Long-Term Outcomes

The Diseases can be clustered and followup studies can help in understanding the diseases progression.

A self-reliant and personalized module to help a patient understand the disease journey and ensure knowledge about the disease progression and necessary recommendations to avoid severe conditions. that might require hospitalization. 

Facilitate and provide services to ~25 M people suffering from chronic diseases and ~1 M people suffering from rare diseases, and create a robust model of disease progression understanding in case of rare diseases. The progression protocol can then be replicated within similar communities to identify a patient at an early stage of the disease. 

Mondosano platform is built using web technologies and  communications among patients and stakeholders happen through web profiles, e-mails, sms, and telephonic calls to interact for follow ups with patients. We are developing an app ( android / iOS) which will help the patients to be onboarded easily with call-in features and personalized modules for diseases related conditions identified in the patient. 

The app will also let the patient connect within the community to discuss their patient journey and related experiences. Each patient will have a digital diary embedded in the app which will track the patient journey from asking queries to participating in a clinical trial. The patient journey will enhance the app platform for other patients suffering from the same disease by including methodologies and approaches taken for the patient’s conditions. 

For better patient discovery and recruitments for clinical trials for both rare and chronic diseases, Mondosano is building another AI powered privacy preserving platform, Mondosano Clinical Trials Patients Discovery Platform

 This platform would be equipped with the following modules : 

•  AI assisted Deidentification Platform for maintaining the privacy of the patients

• AI assisted Graph based Relational Dashboard to demonstrate relationships among pharmaceutical companies, patient groups, and Clinical Trial study group 

• Fully Automated AI based Clinical Trial phase selection guidance 

• EMR integrated AI assisted recommendation system in Clinical Trials and Drug Repurposing

Our technology driven and AI powered clinical trial engagement platform and patients advocacy collaborations would help patients in their journey to fight the stigma. 

Working at Mondosano only requires one thing - being motivated to drive change in healthcare and following our purpose to enable better health for anyone.

 The Mondosano team ensures that each patient is provided with equitable healthcare approaches. We ensure equitable access to disease study participation, clinical trial participation, community collaboration for better patient journey. 

From a par­ticipation perspective, an equitable approach can provide frequent follow up, better disease management, unique and exclusive access to novel therapies.

From an equitable and diverse population patient participation is important to ensure better outcomes for the treatment landscape. 

From disease biology, to generalizability of the findings to the population as a whole, and to undertake subgroup analyses to determine if ethnic origin is associated with variation in the effectiveness of the intervention, all these points help in achieving an equitable diversified patient platform for rare and chronic diseases. 

Our business model enables B2B-customers to benefit from efficient recruitment and targeted engagement.

• Patient Recruitment - Referring informed patients to clinical trials (biopharmaceutical, medical technology & digital health) in 3-12 months campaigns. Success-based fees per patient referral and/or acceptance in study

• Patient Insights - Collecting qualitative & quantitative insights of specific patient populations over 1-6 months for better therapy design. Project fees depending on panel size, difficulty and complexity (CRO model).

• Digital Marketing - Informing patients about specific offerings, new products or events matching their profile in 1-3-month campaigns.  Fixed-price campaigns for specific patient segments and channels

Feasibility and recruitment for clinical trials is our key value proposition and provides the largest revenue share per project as well as database growth.

Mondosano has just completed a financing round to accelerate growth after the pandemic. In addition, resources from our strategic investor with a health media background can be used to competitively scale content and engagement activities. With doubling of our current project volume break even for the agency business model is expected to be achieved.

Mondosano can build on cash flow from our running digital CRO business and was marginally profitable just before the pandemic. Therefore we are optimistic to return to this performance with the current restart of the clinical trial recruiting business and will stepwise expand our operations into other European countries via partnerships and own operations.

Additional funding is needed to take the current platform to another level. Providing much more specific content to patients, strengthening the offerings in the field of rare disease in collaboration with patient organizations, and advancing the Mondosano Clinical Trials Patients Discovery Platform.